In all, 3872 urine specimens were screened for lysergic acid diethylamide (LSD) using the CEDIA DAU LSD assay. Forty-eight samples, mainly from psychiatric patients or drug abusers, were found to be LSD positive, but only 13 (27%) of these could be confirmed by high-performance liquid chromatography with fluorescence detection (HPLC-FLD) following immunoaffinity extraction (IAE). Additional analysis for I.SD using the DPC Coat-a-Count RIA was performed to compare the two immunoassay screening methods. Complete agreement between the DPC RIA assay and HPLC-FLD results was observed at concentrations below a cutoff concentration of 500 pg/mL. Samples that were LSD positive in the CEDIA DAU assay but not confirmed by HPLC-FLD were also investigated for interfering compounds using REMEDI HS drug-profiling system. REMEDI HS analysis identified 15 compounds (parent drugs and metabolites) that are believed to cross-react in the CEDIA DAU LSD assay: ambroxol, prilocaine, pipamperone, diphenhydramine, metoclopramide, amitriptyline, doxepine, atracurium, bupivacaine, doxylamine, lidocaine, mepivacaine, promethazine, ranitidine, and tramadole. The IAE/HPLC-FLD combination is rapid, easy to perform and reliable. It can reduce costs when standard, rather than more advanced, HPLC equipment is used, especially for labs that perform analyses for LSD infrequently. The chromatographic analysis of LSD, nor-LSD, and iso-LSD is not influenced by any of the tested cross-reacting compounds even at a concentration of 100 ng/mL.
Introduction
After oral ingestion, lysergic acid diethylamide (LSD) undergoes rapid and extensive biotransformation by N-demethylation, N-deethylation, and aromatic hydroxylation (1) . Metabolites that have been found in urine include N-demethyl-LSD (nor-LSD) (2, 3) , lysergic acid ethylamide (LAE), iso-LAE, monooxylated LSD (4) , and glucuronide conjugates of C-13 and C-14 hydroxylated LSD (1, 2) . In addition, 2-oxo-3-hydroxy lysergic acid diethylamide (O-H-LSD) was found in human urine specimens at mean concentrations up to 43 times higher than that of LSD (4, 5) . Iso-LSD and iso-nor-LSD are presumed to be impurities (1, 6) . The elimination half-life is approximately 3-5 h for LSD (7, 8) and 10 h for nor-LSD (2) . Cumulative urinary excretion profiles showed that the amount of LSD and nor-LSD excreted in urine represents 0.9% and 1.2% of a single dose (1 IJg/kg) administered orally to an adult volunteer (2) .
Different isotopic immunoassays (RIA Abuscreen and DPC Coat-a-Count) can be used for screening for LSD in urine. However, radioimmunoassays (RIAs) are increasingly being replaced by non-isotopic and fully automated techniques that have a smaller environmental impact such as CEDIA, ELISA, EMIT, Abuscreen OnLine, or Microplate EIA (9-13). In comparative studies with the CEDIA, RIA, and other immunoassays, DPC Coat-a-Count (DPC RIA) was the assay for which confirmation by gas chromatography-mass spectrometry (GC-MS) showed the best agreement (11, 12) .
A number of analytical techniques are used for the determination of LSD from body fluids. These include techniques such as high-performance liquid chromatography coupled with fluorimetry (HPLC-FLD) (14) , HPLC-MS (15), capillary electrophoresis-MS (7), LC-MS (8, 16, 17) , LC-MS-MS (4, 18, 19) , GC (20) , GC-MS (21) , and GC-MS-MS (3).
The LSD confirmation method has to be specific, sensitive, and easy to perform. These requirements depend strongly on how well analytes can be separated from interfering compounds in a biological matrix. A very successful method is immunoaffinity extraction (IAE) (22) especially in combination with HPLC-FLD (23), LC-MS (15) , and LC-LC-MS-MS (19) .
We report here on the screening of 3872 urine specimens for LSD using the CEDIA DAU LSD assay and the additional analysis of the positive LSD test results using the DPC RIA assay. For the confirmation of CEDIA DAU LSD positive samples, a commercially available immunoaffinity extraction kit (LSD ImmunElute Extraction, Microgenics Corp., Fremont, CA) was used in combination with HPLC and a highly selective and sensitive fluorescence detector. In addition, CEDIA DAU posi-tive samples that could not be confirmed by HPLC-FLD were subsequently analyzed for interfering substances by using an automated chromatographic detection and identification system, the REMEDI HS drug-profiling system (REMEDI HS). No further investigations were performed on urine samples that tested negative in the CEDIA.
Materials and Methods
The LSD ImmunElute extraction kit, containing LSD ImmunElute resin and PolyPrep disposable extraction columns, was kindly provided by Microgenics Corp. Standard LSD and nor-LSD were obtained from Sigma-Aldrich Chemicals (Deisenhofen, Germany). Lysergic acid methyl-propylamide (LAMPA), 2-oxo-3-hydroxy-LSD, and iso-LSD were purchased from Radian (Austin, TX). Bidestilled water, HPLC-grade acetonitrile, and methanol (J.T. Baker, Deventer, The Netherlands) were used as received. All other solvents and reagents were analytical grade.
Immunoassay screening
The immunoassays were evaluated by testing calibrators and controls. Each of the assays was calibrated according to the manufacturer's instructions (24, 25) . Samples were tested with the CEDIA DAU LSD and DPC RIA assays in the quantitative mode. A cutoff of 500 pg/mL was used in both assays.
CEDIA DAU LSD. The CEDIA DAU LSD assay (Microgenics Corp.) was performed on a Hitachi 912 analyzer (Roche Diagnostics, Indianapolis, IN).
DPC RIA. The immunoassay was purchased from Diagnostic Products Corporation (DPC, Los Angeles. CA). The samples were counted in a Multicrystall-T-Scintillation Counter (LB 2104. Laboratorium Prof. Dr. Berthold. Bad Wildbad, Germany).
Confirmation method
LSD ImmunElute extraction. Usually 3 mL of each sample was centrifuged (Eppendorf Centrifuge 5415C) before using the LSD lmmunElute extraction kit. The centrifuged specimen was incubated with the affinity resin, the resin was washed and the bound drug eluted in a small volume of methanol according to the manufacturer's instructions (26) . The remaining eluate was evaporated to dryness under a gentle stream of nitrogen at 60~ The dry residue was finally dissolved in 150 IJL of mobile phase, and a 50-IJL aliquot was injected into the HPLC.
HPLC-FLD. The hardware of the HPLC-FLD system consisted of an HPLC pump (model 2150, LKB Bromma, Sweden), a fluorescence spectrometer, which was used as the detector (model LS-4), and a recorder (model 561, both Perkin Elmer, Beaconsfield, Buckinghamshire, England). The detector was operated at an excitation wavelength of 315 nm (slit: 10 nm), and the fluorescence emission was monitored at 420 nm (slit: 20 nm).
The analytical column was a LiChrospher t00 RP 8 cartridge (150 x 4.0 mm, 5 1Jm) purchased from VDS Optilab (Montabaur, Germany). The mobile phase consisted of acetonitrile/50mM potassium phosphate buffer pH 2.3 (34:66, v/v). It was filtered and degassed through a 0.22-1Jm membrane filter (Millipore, MA) prior to use. The mobile phase flow was set isocratically at 0.5 mL/min. For quantitation, a nine-point curve of LSD and nor-LSD was constructed (20, 40, 60 , 80, 100, 250, 300, 400, and 500 pg/mL). Each calibration was linear in the range tested. The detection limit (LOD) was 20 pg/mL (LSD, nor-LSD). The limits of quantitation (LOQ) were 60 pg/mL (LSD) and 70 pg/rnL (nor-LSD) using a sample volume of 3 mL. The recovery was 89% _+ 8% for LSD.
Drug screening
For sample analysis, 1 mL of specimen was centrifuged and mixed with 0.2 mL of internal standard combination according to the manufacturer's directions. The semiquantitation of the drug was carried out by using the response factors (RFs) of the REMEDI HS drug library listing (version 4.3X.11/5.3X.11). Where no RF value was available for a metabolite, the RF value of the parent drug was used.
Cross-reactivity testing
Compounds believed to cause LSD false-positive results were tested separately for cross-reactivity in the CEDIA DAU LSD assay. For this purpose, drug-free urine was spiked with the likely interfering compound. Test concentrations were in the same range as listed in the cross-reactivity performance guide of Microgenics (27) .
Results and Discussion
A total number of 3872 specimens of different origin (psychiatric patients, drug abusers, intensive care patients) were screened for LSD under CEDIA conditions. Forty-eight urine specimens tested LSD positive. Only 13 (27%) of these were also positive in the DPC RIA and confirmed by HPLC-FLD (Table I) . Five samples contained only LSD and eight samples LSD and nor-LSD. HPLC-FLD measured concentrations of LSD ranged from 82 to 14,000 pg/mL, and those of nor-LSD measured from 70 to 800 pg/mL. In general, both immunoassays tend to give higher readings for LSD than HPLC-FLD. A cross-reaction with other LSD metabolites seemed to be possible. Therefore, available LSD metabolites and analogues were tested for cross-reactivity.
The cross-reactivity of iso-LSD, nor-LSD, and O-H-LSD was less than 1% (Table II) and similar to the findings of Verstraete et al. (28) . Therefore, the discrepancy between CEDIA and Retention data are expressed as capacity ratios (k') which are defined by k'= (tR-to)/to, where tR and to are the retention times of the analyte (t R) and a nonretained compound (to), respectively. The retention of methanol (0.05 mglmL) was used to determine to.
able) for example, might be responsible for this phenomenon. Thirty-five samples were positive in the CEDIA DAU LSD test, but not confirmed by HPLC-FLD. These specimens were investigated for interfering substances using the REMEDI HS drug-profiling system. The results of 25 samples are summarized in Table III . Five medications were identified in seven samples. The following drugs, including metabolites, were found: bupivacaine (0.1 pg/mL), ambroxol (4.0 pg/mL), lidocaine (7.9 pg/mL), pipamperone and metabolites (4.7, 11.8, and 21 pg/mL), and tramadole and metabolites (800 ~g/mL). The following drugs including metabolites were identified in combination with other drugs: monoethylglycinexylidide (MEGX; < 0.1-2.9 pg/mL), lidocaine (< 0.1-3.3 pg/mL), doxepine (0.5-16 pg/mL), diphenhydramine (1.7-110 pg/mL), amitriptyline, atracurium (2.4 l~g/mL), bupivacaine (2.7), pipamperone (6.8-47.2 pg/mL), ambroxol (7.4-9.2 pg/mL), metoclopramide (7.6-87.6 pg/mL), mepivacaine (15 ~lg/mL), ranitidine (18.2--840 pg/mL), prilocaine (44 pg/mL), promethazine (82 pg/mL), and doxylamine (1100 pg/mL).
Ambroxol is already known to interfere (29) . Interference by phenothiazines, butyrophenones, and anti-Parkinson drugs was assumed by Verstraete and Steyaert (12) . Bupivacaine, doxylamine, lidocaine, mepivacaine, promethazine, ranitidine, and tramadole are reported not to produce positive results even in concentrations up to 500 pg/mL (27) .
Drug-free urine was spiked with those previously identified that had not yet been tested for cross-reactivity in other studies. According to the cross-reactivity performance guide of Microgenics (27) the samples contained concentrations of the target compound several times higher than those normally found in urine samples. The spiked urine samples were tested in both immunoassays. The results are given in Table IV .
It seems that especially the metabolites of the drugs crossreact in the CEDIA DAU LSD. This is demonstrated by sample 12a (urine) and 12b (stomach) for metoclopramide and sample 23a (urine) and 23b (stomach) for tramadole. Although these urine samples tested LSD positive, analysis of the stomach content produced no positive result. A predominant crossreaction of drug metabolites is also evidenced by urine samples 17 and 18, which were obtained from psychiatric patients who had consumed pipamperone and doxepine in the prescribed dosage without any further medications or drugs.
Several identified drugs and metabolites were tested for interference under HPLC conditions. Each compound was dissolved in eluent and injected separately. The compounds are listed in alphabetical order in Table V . Only metoclopramide and the ergot-related alkaloids except O-H-LSD produced a signal in the HPLC system. When using the LSD ImmunElute extraction kit an unspecific coextraction of metoclopramide may influence the detection of LSD. Therefore, we spiked drug-free urine with metoclopramide in final concentrations of 1, 10, and 100 pg/mL. Following immunoaffinity extraction combined with HPLC-FLD, no signal was recognized in the chromatogram.
The phenomenon of drugs or metabolites cross-reacting with the antibody, which we observed in the CEDIA DAU LSD assay, did not occur in the LSD ImmunElute extraction kit. To determine the recovery of LSD in the presence of other compounds, six patient specimens (samples 6, 8, 9, 15, 22, and 23a) were spiked with 500 pg/mL of LSD and tested for selective extraction. The recovery rate of LSD ranged from 72 to 85% in the presence even of high concentrations of tramadole (sample no. 23a). This final experiment clearly demonstrates the high selectivity of the IAE/HPLC-FLD method in the detection of LSD.
Conclusions
In our study, we found complete agreement between the resuits of DPC RIA (cutoff level: 500 pg/mL) and those we obtained with HPLC-FLD. In this regard, in comparison with CEDIA DAU LSD, DPC RIA is the more suitable immunoassay for screening because cross-reacting is nearly excluded and less confirmatory testing is necessary. On the other hand, DPC RIA is more time consuming because it cannot be run in a fully automated mode, and it has a higher environmental impact.
The false-positive results in the CEDIA DAU LSD related to specimens that came from psychiatric patients or patients in intensive care. We believe the following parent drugs and/or the metabolites are responsible for the false-positive LSD results in the non-isotopic immunoassay: ambroxol, prilocaine, pipamperone, diphenhydramine, metoclopramide, amitriptyline, doxepine, atracurium, bupivacaine, doxylamine, lidocaine, mepivacaine, promethazine, ranitidine, and tramadole.
Because of the reduced sensitivity of the CEDIA DAU LSD assay for iso-LSD, nor-LSD, and O-H-LSD, it seems to be possible that it did not detect all LSD-positive urine samples. Therefore, a more sensitive screening method that is capable of detecting LSD metabolites should be developed.
The tested combination LSD ImmunElute extraction kit/HPLC-FLD was suitable for the confirmation of LSD-positive urines. This method showed high selectivity for LSD and nor-LSD and simplifies sample preparation for the quantitative determination under routine conditions.
